ENDOCYTE INC's ticker is ECYT and the CUSIP is 29269A102. A total of 98 filers reported holding ENDOCYTE INC in Q2 2015. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $406,000 | -17.5% | 159,176 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $492,000 | -4.1% | 159,176 | -0.5% | 0.00% | 0.0% |
| Q2 2016 | $513,000 | +10.8% | 159,905 | +7.0% | 0.00% | 0.0% |
| Q1 2016 | $463,000 | -22.2% | 149,432 | +0.6% | 0.00% | 0.0% |
| Q4 2015 | $595,000 | -12.4% | 148,493 | +0.1% | 0.00% | 0.0% |
| Q3 2015 | $679,000 | -12.4% | 148,306 | -0.7% | 0.00% | 0.0% |
| Q2 2015 | $775,000 | +13.1% | 149,313 | +36.5% | 0.00% | 0.0% |
| Q1 2015 | $685,000 | 0.0% | 109,423 | +0.4% | 0.00% | 0.0% |
| Q4 2014 | $685,000 | +2.4% | 108,941 | -1.0% | 0.00% | 0.0% |
| Q3 2014 | $669,000 | -5.6% | 109,999 | +2.2% | 0.00% | 0.0% |
| Q2 2014 | $709,000 | -64.7% | 107,595 | +27.7% | 0.00% | -66.7% |
| Q1 2014 | $2,006,000 | +122.1% | 84,232 | -0.4% | 0.00% | +200.0% |
| Q4 2013 | $903,000 | -21.8% | 84,597 | -2.2% | 0.00% | -50.0% |
| Q3 2013 | $1,154,000 | +8.6% | 86,537 | +6.9% | 0.00% | 0.0% |
| Q2 2013 | $1,063,000 | – | 80,956 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 4,300,000 | $59,340,000 | 17.76% |
| RA Capital Management | 5,649,884 | $77,968,000 | 5.06% |
| Avoro Capital Advisors LLC | 5,695,200 | $78,594,000 | 3.03% |
| Crosspoint Capital Strategies, LLC | 107,620 | $1,485,000 | 2.84% |
| Ghost Tree Capital, LLC | 500,000 | $6,900,000 | 2.03% |
| EMORY UNIVERSITY | 205,295 | $2,833,000 | 1.88% |
| Asymmetry Capital Management, L.P. | 103,159 | $1,424,000 | 1.40% |
| NEXTHERA CAPITAL LP | 596,000 | $8,225,000 | 1.27% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,324,299 | $32,075,000 | 1.13% |
| PFM Health Sciences, LP | 4,068,608 | $56,147,000 | 0.88% |